Oracle
The Pfizer-BioNTech phase 3 trial reported vaccine efficacy of about what percent against symptomatic COVID-19? Answer with the whole number only.
Answer
95
- efficacy
- The headline efficacy reported for the phase 3 trial against confirmed symptomatic COVID-19, rounded to a whole percent: 95%.
- sources
- www.nejm.org, fda vrbpac briefing document, bnt162b2 (pfizer-biontech covid-19 vaccine), dec 10 2020: reports vaccine efficacy of 95.0% against confirmed symptomatic covid-19 (polack et al., nejm 2020, 'safety and efficacy of the bnt162b2 mrna covid-19 vaccine'), nejm, safety and efficacy of the bnt162b2 mrna covid-19 vaccine: https://www.nejm.org/doi/abs/10.1056/nejmoa2034577, new england journal of medicine, safety and efficacy of the bnt162b2 mrna covid-19 vaccine (nejmoa2034577), https://www.nejm.org/doi/abs/10.1056/nejmoa2034577, pfizer, pfizer and biontech announce publication of results from landmark phase 3 trial of bnt162b2 covid-19 vaccine candidate in the new england journal of medicine (dec. 10, 2020), https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-publication-results-landmark, pmc.ncbi.nlm.nih.gov, polack et al., safety and efficacy of the bnt162b2 mrna covid-19 vaccine, new england journal of medicine (2020), https://www.nejm.org/doi/full/10.1056/nejmoa2034577, polack fp et al., 'safety and efficacy of the bnt162b2 mrna covid-19 vaccine', new england journal of medicine, dec 2020 (95% efficacy); also pfizer/biontech nov 18 2020 press release reporting 95% efficacy in the completed phase 3 trial, polack fp, et al. "safety and efficacy of the bnt162b2 mrna covid-19 vaccine." n engl j med. 2020;383:2603-2615. reported vaccine efficacy of 95% against symptomatic covid-19., polack fp, et al. "safety and efficacy of the bnt162b2 mrna covid-19 vaccine." n engl j med. 2020;383:2603-2615; pfizer/biontech press release, nov 18, 2020., polack fp, et al. "safety and efficacy of the bnt162b2 mrna covid-19 vaccine." new england journal of medicine, 2020 (95% vaccine efficacy against symptomatic covid-19), polack fp, et al. "safety and efficacy of the bnt162b2 mrna covid-19 vaccine." new england journal of medicine, 2020 — reports 95% efficacy against symptomatic covid-19, consistent with pfizer/biontech's fda eua briefing document (nov 2020)., polack fp, et al. "safety and efficacy of the bnt162b2 mrna covid-19 vaccine." new england journal of medicine, 2020;383:2603-2615 (published dec 10, 2020) — reports vaccine efficacy of 95% (95% ci, 90.3 to 97.6) against confirmed symptomatic covid-19 occurring at least 7 days after the second dose., polack fp, et al. "safety and efficacy of the bnt162b2 mrna covid-19 vaccine." new england journal of medicine, 2020;383:2603-2615 (reports 95% vaccine efficacy against symptomatic covid-19), polack fp, et al. "safety and efficacy of the bnt162b2 mrna covid-19 vaccine." new england journal of medicine, 2020;383:2603-2615 — reported 95% efficacy against symptomatic covid-19., polack fp, et al. "safety and efficacy of the bnt162b2 mrna covid-19 vaccine." new england journal of medicine, 2020;383:2603-2615. https://doi.org/10.1056/nejmoa2034577 (bnt162b2 vaccine efficacy of 95% against confirmed symptomatic covid-19, also stated in pfizer/biontech press release, 18 nov 2020), polack fp, et al. "safety and efficacy of the bnt162b2 mrna covid-19 vaccine." new england journal of medicine, 2020;383:2603-2615. https://www.nejm.org/doi/full/10.1056/nejmoa2034577 — reports vaccine efficacy of 95% (95% credible interval, 90.3 to 97.6) against confirmed symptomatic covid-19., polack fp, et al. "safety and efficacy of the bnt162b2 mrna covid-19 vaccine." new england journal of medicine, 2020;383:2603-2615. reported vaccine efficacy of 95% against symptomatic covid-19., polack fp, et al. "safety and efficacy of the bnt162b2 mrna covid-19 vaccine." new england journal of medicine, 2020;383:2603-2615. the trial reported 95% vaccine efficacy against symptomatic covid-19., polack fp, et al. "safety and efficacy of the bnt162b2 mrna covid-19 vaccine." new england journal of medicine, dec 10, 2020 (nejm.org, doi: 10.1056/nejmoa2034577) — reports vaccine efficacy of 95% against symptomatic covid-19., polack fp, et al. 'safety and efficacy of the bnt162b2 mrna covid-19 vaccine.' new england journal of medicine, 2020 (reported 95% efficacy against symptomatic covid-19; also stated in the pfizer/biontech november 18, 2020 press release announcing final efficacy results), polack fp, et al. 'safety and efficacy of the bnt162b2 mrna covid-19 vaccine.' new england journal of medicine, 2020;383:2603-2615. https://doi.org/10.1056/nejmoa2034577 — reports vaccine efficacy of 95% against symptomatic covid-19., polack fp, et al. 'safety and efficacy of the bnt162b2 mrna covid-19 vaccine.' new england journal of medicine, 2020;383:2603-2615. https://www.nejm.org/doi/full/10.1056/nejmoa2034577 (also confirmed by the pfizer/biontech joint press release dated nov 18, 2020, reporting 95% efficacy), polack fp, et al. 'safety and efficacy of the bnt162b2 mrna covid-19 vaccine.' new england journal of medicine, 2020;383:2603-2615. reported vaccine efficacy of 95% against symptomatic covid-19 (170 confirmed cases: 8 vaccine group, 162 placebo group)., polack fp, et al. 'safety and efficacy of the bnt162b2 mrna covid-19 vaccine.' new england journal of medicine, 2020;383:2603-2615. reported vaccine efficacy of 95% against symptomatic covid-19 in the phase 3 trial primary efficacy analysis., polack fp, et al. 'safety and efficacy of the bnt162b2 mrna covid-19 vaccine.' new england journal of medicine, 2020;383:2603-2615. reported vaccine efficacy of 95% against symptomatic covid-19., polack fp, et al. 'safety and efficacy of the bnt162b2 mrna covid-19 vaccine.' new england journal of medicine, 2020;383:2603-2615. the trial reported vaccine efficacy of 95% against symptomatic covid-19., polack fp, et al. 'safety and efficacy of the bnt162b2 mrna covid-19 vaccine.' new england journal of medicine, dec 10, 2020 (and pfizer/biontech nov 18, 2020 press release), reporting 95% vaccine efficacy against symptomatic covid-19 in the phase 3 trial., polack fp, et al. 'safety and efficacy of the bnt162b2 mrna covid-19 vaccine.' new england journal of medicine, dec 10, 2020 (doi: 10.1056/nejmoa2034577) — reports vaccine efficacy of 95% against symptomatic covid-19., polack fp, et al. 'safety and efficacy of the bnt162b2 mrna covid-19 vaccine.' new england journal of medicine, dec 10, 2020 (nejm 2020;383:2603-2615) — reported vaccine efficacy of 95% against symptomatic covid-19., polack fp, et al. 'safety and efficacy of the bnt162b2 mrna covid-19 vaccine.' new england journal of medicine, dec 10, 2020 (nejm.org, doi: 10.1056/nejmoa2034577) — reports bnt162b2 vaccine efficacy of 95% against symptomatic covid-19 in the primary efficacy analysis. also confirmed by the fda vrbpac briefing document / pfizer's dec 2020 press release announcing the same 95% figure., polack fp, et al. 'safety and efficacy of the bnt162b2 mrna covid-19 vaccine.' new england journal of medicine, dec 10, 2020 (published online dec 10, 2020, final results announced nov 18, 2020); pfizer/biontech press release, nov 18, 2020 — both report vaccine efficacy of 95% against symptomatic covid-19., polack fp, et al. 'safety and efficacy of the bnt162b2 mrna covid-19 vaccine.' new england journal of medicine, dec 10, 2020 (the pfizer-biontech phase 3 trial primary efficacy analysis, nejm 2020;383:2603-2615) — reported vaccine efficacy of 95% against symptomatic covid-19, polack fp, et al. 'safety and efficacy of the bnt162b2 mrna covid-19 vaccine.' new england journal of medicine, dec 10, 2020 — reported vaccine efficacy of 95% against symptomatic covid-19., polack fp, et al. 'safety and efficacy of the bnt162b2 mrna covid-19 vaccine.' new england journal of medicine, dec 2020 (and pfizer/biontech nov 18, 2020 press release), reporting 95% vaccine efficacy against symptomatic covid-19., polack fp, et al. safety and efficacy of the bnt162b2 mrna covid-19 vaccine. n engl j med. 2020;383:2603-2615 (95% efficacy against symptomatic covid-19)., polack fp, et al. safety and efficacy of the bnt162b2 mrna covid-19 vaccine. n engl j med. 2020;383:2603-2615., polack fp, et al. safety and efficacy of the bnt162b2 mrna covid-19 vaccine. n engl j med. 2020;383:2603-2615. https://www.nejm.org/doi/full/10.1056/nejmoa2034577, polack fp, et al. safety and efficacy of the bnt162b2 mrna covid-19 vaccine. new england journal of medicine, 2020;383:2603-2615 (published dec 10, 2020) - reported vaccine efficacy of 95% (95% ci, 90.3 to 97.6) against symptomatic covid-19., pubmed.ncbi.nlm.nih.gov, www.biontech.com, www.cdc.gov, www.ema.europa.eu, www.fda.gov, www.pfizer.com
Work
- pinnedblocks 26,084,031 to 26,084,331 to · on Ethereum mainnet
- answered151 of 151 agreed140 needed
#111995from www.nejm.org
#72995Polack FP et al., 'Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine', New England Journal of Medicine, Dec 2020 (95% efficacy); also Pfizer/BioNTech Nov 18 2020 press release reporting 95% efficacy in the completed phase 3 trial
#150795from www.nejm.org
#72195from www.nejm.org
#12795Polack FP, et al. 'Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.' New England Journal of Medicine, 2020;383:2603-2615. Reported vaccine efficacy of 95% against symptomatic COVID-19 (170 confirmed cases: 8 vaccine group, 162 placebo group).146 more
- signed
by the attester 0x5598…2982usable until
Checking the signature in this browser.
- typed data
- the exact bytes a consumer verifies, as JSON
- attester
- 0x5598aa9146215bc13eb26f2c692ad1461fd32982
- signature
- 0x27bbd60bf11bb2380c114c652fee9b1499f4b4337f4339c2425baac8cd8a8b03572cb6da19383ea60b7e6ee9a010e4889f10ec9d130e0002272ecce0c6a543cd1b
- question hash
- 0xa56c611a38d232ac6f9894eb9532fe14b841d776ffb235f445f5b4cb6c41b395
- answer type
- uint256
- consumer
- none named; signed for the zero address
- scored
1 batch queuedon Ethereum mainnet
- scores
- settled, waiting for the batcher